PHAT
Phathom Pharmaceuticals Inc.
$11.10
-$0.23(-2.03%)
38
Overall
40
Value
30
Tech
44
Quality
Market Cap
$909.22M
Volume
833.41K
52W Range
$2.82 - $18.31
Target Price
$23.70
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | -- | $682.0K | $55.3M | $175.1M | ||
| Total Revenue | -- | -- | -- | -- | $682.0K | $55.3M | $175.1M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | -- | -- | $167.0K | $8.0M | $22.6M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | -- | $515.0K | $47.3M | $152.5M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $106.2M | $125.7M | $135.1M | $172.4M | $167.8M | $324.7M | $312.5M | ||
| Research & Development | $20.4M | $98.1M | $72.3M | $71.4M | $49.9M | $34.1M | $32.8M | ||
| Research Expense | $20.4M | $98.1M | $72.3M | $71.4M | $49.9M | $34.1M | $32.8M | ||
| Selling, General & Administrative | $6.9M | $27.5M | $62.7M | $101.0M | $117.9M | $290.7M | $279.7M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $61.3M | -- | ||
| General & Administrative Expenses | $6.9M | $27.5M | $62.7M | $101.0M | $117.9M | $290.7M | $279.7M | ||
| Salaries & Wages | $-406.0K | -- | -- | -- | $45.0M | $24.0M | $28.7M | ||
| Depreciation & Amortization | $-8.0K | $300.0K | $500.0K | $600.0K | $600.0K | $800.0K | -- | ||
| Depreciation & Amortization | $-8.0K | $300.0K | $500.0K | $600.0K | $600.0K | -- | -- | ||
| Other Operating Expenses | $78.9M | $-762.0K | $-702.0K | $-623.0K | $-632.0K | -- | -- | ||
| OPERATING INCOME | |||||||||
| Operating income | $-106.2M | $-125.7M | $-135.1M | $-172.4M | $-167.3M | $-277.5M | $-160.0M | ||
| EBITDA | $-250.5M | $-124.2M | $-136.6M | $-169.8M | $-203.4M | $-259.3M | $-149.5M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $4.2M | $4.6M | $6.8M | $27.3M | $42.0M | $72.0M | $68.1M | ||
| Intinc | $-48.5M | $1.1M | $41.0K | $2.1M | $7.9M | $15.2M | $7.0M | ||
| Net Non-Operating Interest Income/Expense | $-52.6M | $-3.5M | $-6.7M | $-25.2M | $7.9M | $-56.9M | $-61.1M | ||
| Other Income/Expense | $96.3M | $-87.0K | $2.1M | $-110.0K | $188.0K | $8.0K | $190.0K | ||
| Other Special Charges | $-96.3M | $87.0K | $-2.1M | $-110.0K | $-188.0K | $-8.0K | $-190.0K | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-251.0M | $-124.5M | $-137.1M | $-170.4M | $-205.9M | $-262.3M | $-153.1M | ||
| Pre-Tax Income | $-255.1M | $-129.1M | $-143.9M | $-197.7M | $-159.6M | $-334.3M | $-221.2M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-55.0K | $-68.0K | $-4.0K | -- | $-4.3M | -- | -- | ||
| NET INCOME | |||||||||
| Net Income | $-255.1M | $-129.1M | $-143.9M | $-197.7M | $-201.6M | $-334.3M | $-221.2M | ||
| Net Income (Continuing Operations) | $-255.1M | $-129.1M | $-143.9M | $-197.7M | $-201.6M | $-334.3M | $-221.2M | ||
| Net Income (Discontinued Operations) | $-255.1M | $-129.1M | $-143.9M | $-197.7M | $-201.6M | $-334.3M | $-221.2M | ||
| Net Income (Common Stockholders) | $-255.1M | $-129.1M | $-143.9M | $-197.7M | $-201.6M | $-334.3M | $-221.2M | ||
| Normalized Income | -- | -- | $-143.9M | -- | -- | -- | $-219.0M | ||
| TOTALS | |||||||||
| Total Expenses | $106.2M | $125.7M | $135.1M | $172.4M | $168.0M | $332.7M | $335.1M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $11.4M | $33.2M | $37.0M | $39.1M | $51.3M | $63.2M | $72.9M | ||
| Average Shares Outstanding (Diluted) | $11.4M | $33.2M | $37.0M | $39.1M | $51.3M | $63.2M | $72.9M | ||
| Shares Outstanding | $29.0M | $31.3M | $31.7M | $42.0M | $58.5M | $69.6M | $78.8M | ||
| Basic EPS | -- | $-3.88 | $-3.89 | $-5.05 | $-3.93 | $-5.29 | $-3.03 | ||
| Basic EPS (Continuing Operations) | -- | $-3.88 | $-3.89 | $-5.05 | $-3.93 | $-5.29 | $-3.03 | ||
| Diluted EPS | $-22.45 | $-3.88 | $-3.89 | $-5.05 | $-3.93 | $-5.29 | $-3.03 | ||
| Diluted EPS (Continuing Operations) | $-22.45 | -- | -- | $-5.05 | $-3.93 | $-5.29 | $-3.03 | ||
| OTHER METRICS | |||||||||
| Other Gand A | $6.9M | $27.5M | $62.7M | $101.0M | $117.9M | $290.7M | $279.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PHAT | $11.10 | -2.0% | 833.41K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Phathom Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW